TY - JOUR
T1 - Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific
AU - McGrath, Deirdre
AU - Pantelidis, Panos
AU - Southcott, Anne Marie
AU - Black, Carol M.
AU - Du Bois, Roland M.
PY - 2001
Y1 - 2001
N2 - Background: Previous studies have revealed that tumour necrosis factor (TNF)-α is upregulated in fibrosing alveolitis (FA) in humans. The aim of this study was to compare the TNF-α secretory profile of alveolar macrophages (AMs) and peripheral blood monocytes (Mos) of patients with cryptogenic FA and systemic sclerosis (SSc), a rheumatological disorder in which lung fibrosis can occur. In particular, we wished to assess whether TNF-α levels differ between SSc patients with FA (FASSc) and a nonfibrotic group. Methods: The reverse haemolytic plaque assay was used to evaluate the secretion of cytokine at a single cell level while immunostaining allowed subtyping of AMs and Mos. Results: This study demonstrated a difference in total TNF-α levels produced by AMs when the levels in subjects with FA (cryptogenic FA and FASSc) were compared to levels in either SSc patients without FA (P=0.0002) or normal healthy controls (P<0.001). In addition, AMs from patients with FASSc secreted more TNF-α than those of patients with no FA (P=0.003). In contrast, there were no significant differences in Mo TNF-α secretion between the groups. A positive correlation was found between total TNF-α level and number of neutrophils obtained by bronchoalveolar lavage from patients with FA (r=0.49, P<0.04). Finally, it was demonstrated that there was significant heterogeneity of TNF-α secretion and that a numerically significant subset of mononuclear phagocytes, RFD7, was responsible for more than 80% of TNF-α production. Conclusion: By demonstrating the primary cell source of TNF-α in FASSc, more accurately targeted, possibly localized, anti-TNF strategies might be employed with success in the future.
AB - Background: Previous studies have revealed that tumour necrosis factor (TNF)-α is upregulated in fibrosing alveolitis (FA) in humans. The aim of this study was to compare the TNF-α secretory profile of alveolar macrophages (AMs) and peripheral blood monocytes (Mos) of patients with cryptogenic FA and systemic sclerosis (SSc), a rheumatological disorder in which lung fibrosis can occur. In particular, we wished to assess whether TNF-α levels differ between SSc patients with FA (FASSc) and a nonfibrotic group. Methods: The reverse haemolytic plaque assay was used to evaluate the secretion of cytokine at a single cell level while immunostaining allowed subtyping of AMs and Mos. Results: This study demonstrated a difference in total TNF-α levels produced by AMs when the levels in subjects with FA (cryptogenic FA and FASSc) were compared to levels in either SSc patients without FA (P=0.0002) or normal healthy controls (P<0.001). In addition, AMs from patients with FASSc secreted more TNF-α than those of patients with no FA (P=0.003). In contrast, there were no significant differences in Mo TNF-α secretion between the groups. A positive correlation was found between total TNF-α level and number of neutrophils obtained by bronchoalveolar lavage from patients with FA (r=0.49, P<0.04). Finally, it was demonstrated that there was significant heterogeneity of TNF-α secretion and that a numerically significant subset of mononuclear phagocytes, RFD7, was responsible for more than 80% of TNF-α production. Conclusion: By demonstrating the primary cell source of TNF-α in FASSc, more accurately targeted, possibly localized, anti-TNF strategies might be employed with success in the future.
KW - Fibrosing alveolitis
KW - Haemolytic plaque
KW - Macrophages
KW - Monocytes
KW - Systemic sclerosis
KW - Tumour necrosis factor (TNF)-α
UR - http://www.scopus.com/inward/record.url?scp=0035722803&partnerID=8YFLogxK
U2 - 10.1186/rr87
DO - 10.1186/rr87
M3 - Article
C2 - 11737936
AN - SCOPUS:0035722803
SN - 1465-9921
VL - 2
SP - 365
EP - 372
JO - Respiratory Research
JF - Respiratory Research
IS - 6
ER -